In last trading session, Bicara Therapeutics Inc (NASDAQ:BCAX) saw 2.8 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $13.01 trading at -$1.49 or -10.28% at ring of the bell on the day assigns it a market valuation of $707.95M. That closing price of BCAX’s stock is at a discount of -115.91% from its 52-week high price of $28.09 and is indicating a premium of 14.68% from its 52-week low price of $11.10. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.64 million shares which gives us an average trading volume of 453.61K if we extend that period to 3-months.

Bicara Therapeutics Inc (NASDAQ:BCAX) trade information

Upright in the red during last session for losing -10.28%, in the last five days BCAX remained trading in the red while hitting it’s week-highest on Friday, 03/07/25 when the stock touched $13.01 price level, adding 22.0% to its value on the day. Bicara Therapeutics Inc’s shares saw a change of -25.32% in year-to-date performance and have moved -12.57% in past 5-day. Bicara Therapeutics Inc (NASDAQ:BCAX) showed a performance of 0.08% in past 30-days. Number of shares sold short was 5.61 million shares which calculate 15.48 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 35 to the stock, which implies a rise of 62.83% to its current value. Analysts have been projecting 35 as a low price target for the stock while placing it at a high target of 35. It follows that stock’s current price would drop -169.02% in reaching the projected high whereas dropping to the targeted low would mean a loss of -169.02% for stock’s current value.

In 2025, company’s earnings growth rate is likely to be around 16.24% while estimates for its earnings growth in next 5 years are of -9.13%.

Bicara Therapeutics Inc (NASDAQ:BCAX)’s Major holders

Insiders are in possession of 0.43% of company’s total shares while institution are holding 86.05 percent of that, with stock having share float percentage of 86.43%. Investors also watch the number of corporate investors in a company very closely, which is 86.05% institutions for Bicara Therapeutics Inc that are currently holding shares of the company.